477 related articles for article (PubMed ID: 17321463)
1. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
[TBL] [Abstract][Full Text] [Related]
2. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice.
Elson CO; Cong Y; Weaver CT; Schoeb TR; McClanahan TK; Fick RB; Kastelein RA
Gastroenterology; 2007 Jun; 132(7):2359-70. PubMed ID: 17570211
[TBL] [Abstract][Full Text] [Related]
4. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation.
Kikly K; Liu L; Na S; Sedgwick JD
Curr Opin Immunol; 2006 Dec; 18(6):670-5. PubMed ID: 17010592
[TBL] [Abstract][Full Text] [Related]
5. New mediators of immunity and inflammation in inflammatory bowel disease.
Monteleone G; Fina D; Caruso R; Pallone F
Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
[TBL] [Abstract][Full Text] [Related]
6. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease.
Abraham C; Cho JH
Annu Rev Med; 2009; 60():97-110. PubMed ID: 18976050
[TBL] [Abstract][Full Text] [Related]
7. Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL-17A expression and inflammation in the intestinal mucosa.
Kim DJ; Kim KS; Song MY; Seo SH; Kim SJ; Yang BG; Jang MH; Sung YC
Clin Immunol; 2012 Sep; 144(3):190-9. PubMed ID: 22836084
[TBL] [Abstract][Full Text] [Related]
8. IL-23/IL-17 biology and therapeutic considerations.
Dong C
J Immunotoxicol; 2008 Jan; 5(1):43-6. PubMed ID: 18382857
[TBL] [Abstract][Full Text] [Related]
9. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion.
Liu Z; Jiu J; Liu S; Fa X; Li F; Du Y
J Autoimmun; 2007; 29(2-3):187-94. PubMed ID: 17804196
[TBL] [Abstract][Full Text] [Related]
10. Understanding the IL-23-IL-17 immune pathway.
McKenzie BS; Kastelein RA; Cua DJ
Trends Immunol; 2006 Jan; 27(1):17-23. PubMed ID: 16290228
[TBL] [Abstract][Full Text] [Related]
11. Immunopathogenesis of inflammatory bowel disease: current concepts.
Bamias G; Cominelli F
Curr Opin Gastroenterol; 2007 Jul; 23(4):365-9. PubMed ID: 17545770
[TBL] [Abstract][Full Text] [Related]
12. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells.
Sasaoka T; Ito M; Yamashita J; Nakajima K; Tanaka I; Narita M; Hara Y; Hada K; Takahashi M; Ohno Y; Matsuo T; Kaneshiro Y; Tanaka H; Kaneko K
Am J Physiol Gastrointest Liver Physiol; 2011 Apr; 300(4):G568-76. PubMed ID: 21193526
[TBL] [Abstract][Full Text] [Related]
13. IL-23-dependent and -independent enhancement pathways of IL-17A production by lactic acid.
Yabu M; Shime H; Hara H; Saito T; Matsumoto M; Seya T; Akazawa T; Inoue N
Int Immunol; 2011 Jan; 23(1):29-41. PubMed ID: 21131367
[TBL] [Abstract][Full Text] [Related]
14. [Immunology in medical practice. IV. Inflammatory bowel diseases: pathogenic starting points for specific therapy].
van Deventer SJ
Ned Tijdschr Geneeskd; 1997 Oct; 141(41):1956-9. PubMed ID: 9550744
[TBL] [Abstract][Full Text] [Related]
15. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy.
Bowman EP; Chackerian AA; Cua DJ
Curr Opin Infect Dis; 2006 Jun; 19(3):245-52. PubMed ID: 16645485
[TBL] [Abstract][Full Text] [Related]
16. [IL-17/IL-23: a new therapeutic target in inflammatory bowel diseases].
Malamut G
Gastroenterol Clin Biol; 2008 Mar; 32(3):354-6. PubMed ID: 18374530
[No Abstract] [Full Text] [Related]
17. Interleukin-12, interleukin-23, and psoriasis: current prospects.
Torti DC; Feldman SR
J Am Acad Dermatol; 2007 Dec; 57(6):1059-68. PubMed ID: 17706835
[TBL] [Abstract][Full Text] [Related]
18. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis.
Guan Q; Ma Y; Hillman CL; Ma A; Zhou G; Qing G; Peng Z
Vaccine; 2009 Nov; 27(50):7096-104. PubMed ID: 19786142
[TBL] [Abstract][Full Text] [Related]
19. IL-12-and IL-23 in health and disease.
Croxford AL; Kulig P; Becher B
Cytokine Growth Factor Rev; 2014 Aug; 25(4):415-21. PubMed ID: 25130295
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in biological therapy for inflammatory bowel disease.
Kurtovic J; Segal I
Trop Gastroenterol; 2004; 25(1):9-14. PubMed ID: 15303463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
